2Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin [J]. Curr Opinion Nephrol Hypertens, 1994,3: 620.
1[1]Teehan B, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Trans-plant Proc, 1996,212:63
2[2]Harnett JD, et al. Congestive heart failure in dialysis patients:prevalence, in-cidence,prognosis and risk factors. Kidney Int, 1995,47:884
3[3]Vanholder R, et al. Contributing factors to the inhibition of phagocytosis inhemodialyzed patients. Kidney Int, 1993,44:208
4[4]Lowrie EG, et al. The relative contribution of measured variables to death riskamong hemodialysis patients, in Friedman E A: Death on hemo dialysis: pre-ventable or inevitable? Boston, MA, Kluwer academic Publisher, 1994,121
5[5]US Renal Date System: The USRD Dialysis Morbidity and Mortality Study(Wave 1). in National Instiutes of Health, National Institute Diabetes and Digestive and Kidney Disease: US renal Date System 1996 Annual Date Report.Bethesda, MD, 1996,45
6[6]Mizuguchi T, et al. Serum transferrin receptor level as an index of the response to erythropoietin therapy for anemia in pre-dialysis patients with chronic renal failure. Nippon Jinzo Gakkai Shi, 1997 Jul,39(5):497
3Aggarwal HK,Nand N,Singh S. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietn[J].Journal of the Association of Physicians of India,2003,(51):170-174.doi:10.1097/PEC.0b013e3181e057b8.
4Van Wyck DB,Roppolo M,Martinez CO. for the united states Iron Sucrose(venofer)clinical Trials Group.A randomized,controlled trial comparing Ⅳ iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD[J].Kidney International,2005,(68):2846-2856.doi:10.1016/j.ajo.2008.05.033.
